NASDAQ:VIVO - Meridian Bioscience Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.57 +0.14 (+0.85 %) (As of 02/15/2019 04:00 PM ET)Previous Close$16.57Today's Range$16.43 - $16.7952-Week Range$13.53 - $19.84Volume1.16 million shsAverage Volume385,228 shsMarket Capitalization$704.04 millionP/E Ratio22.39Dividend Yield3.04%Beta0.41 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio. Receive VIVO News and Ratings via Email Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:VIVO Previous Symbol CUSIP58958410 Webwww.meridianbioscience.com Phone513-271-3700Debt Debt-to-Equity Ratio0.24 Current Ratio6.75 Quick Ratio4.02Price-To-Earnings Trailing P/E Ratio22.39 Forward P/E Ratio22.09 P/E GrowthN/A Sales & Book Value Annual Sales$213.57 million Price / Sales3.30 Cash Flow$0.9584 per share Price / Cash Flow17.29 Book Value$4.20 per share Price / Book3.95Profitability EPS (Most Recent Fiscal Year)$0.74 Net Income$23.84 million Net Margins12.06% Return on Equity19.17% Return on Assets13.36%Miscellaneous Employees585 Outstanding Shares42,489,000Market Cap$704.04 million OptionableOptionable Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions What is Meridian Bioscience's stock symbol? Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO." How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience? Meridian Bioscience declared a quarterly dividend on Friday, January 25th. Shareholders of record on Monday, February 4th will be given a dividend of $0.125 per share on Thursday, February 14th. This represents a $0.50 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Friday, February 1st. View Meridian Bioscience's Dividend History. How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) released its quarterly earnings results on Thursday, January, 24th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The company had revenue of $51.48 million for the quarter, compared to analysts' expectations of $51.50 million. Meridian Bioscience had a return on equity of 19.17% and a net margin of 12.06%. The company's revenue was down 1.5% on a year-over-year basis. During the same period last year, the business earned $0.15 earnings per share. View Meridian Bioscience's Earnings History. When is Meridian Bioscience's next earnings date? Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Meridian Bioscience. What guidance has Meridian Bioscience issued on next quarter's earnings? Meridian Bioscience issued an update on its FY19 earnings guidance on Thursday, January, 24th. The company provided earnings per share guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.76. The company issued revenue guidance of $214-218 million (Flat to +2%), compared to the consensus revenue estimate of $221.13 million.Meridian Bioscience also updated its FY 2019 guidance to $0.74-0.76 EPS. Has Meridian Bioscience been receiving favorable news coverage? Press coverage about VIVO stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Meridian Bioscience earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of Meridian Bioscience's key competitors? Some companies that are related to Meridian Bioscience include Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), Vermillion (VRML), ImmuCell (ICCC), Riot Blockchain (RIOT) and Achieve Life Sciences (ACHV). Who are Meridian Bioscience's key executives? Meridian Bioscience's management team includes the folowing people: Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 51)Mr. Lawrence J. Baldini, Exec. VP of Global Operations (Age 60)Ms. Susan D. Rolih, Consultant (Age 70)Ms. Melissa A. Lueke, Consultant (Age 56)Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51) Who are Meridian Bioscience's major shareholders? Meridian Bioscience's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.85%), Dimensional Fund Advisors LP (4.48%), Geode Capital Management LLC (1.93%), Vaughan Nelson Investment Management L.P. (1.81%), Bank of New York Mellon Corp (1.64%) and Northern Trust Corp (1.32%). Company insiders that own Meridian Bioscience stock include John A Kraeutler, John Mccune Jr Rice, John Mcilwraith and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience. Which major investors are selling Meridian Bioscience stock? VIVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Assenagon Asset Management S.A., New York State Common Retirement Fund, Bank of New York Mellon Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Prudential Financial Inc. and Segall Bryant & Hamill LLC. View Insider Buying and Selling for Meridian Bioscience. Which major investors are buying Meridian Bioscience stock? VIVO stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., WINTON GROUP Ltd, Los Angeles Capital Management & Equity Research Inc., Municipal Employees Retirement System of Michigan, Two Sigma Investments LP, BlackRock Inc., Acadian Asset Management LLC and Natixis Advisors L.P.. Company insiders that have bought Meridian Bioscience stock in the last two years include John A Kraeutler, John Mccune Jr Rice and John Mcilwraith. View Insider Buying and Selling for Meridian Bioscience. How do I buy shares of Meridian Bioscience? Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Meridian Bioscience's stock price today? One share of VIVO stock can currently be purchased for approximately $16.57. How big of a company is Meridian Bioscience? Meridian Bioscience has a market capitalization of $704.04 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe. What is Meridian Bioscience's official website? The official website for Meridian Bioscience is http://www.meridianbioscience.com. How can I contact Meridian Bioscience? Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700. MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)Community Ranking: 1.9 out of 5 ()Outperform Votes: 216 (Vote Outperform)Underperform Votes: 341 (Vote Underperform)Total Votes: 557MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What are the economic characteristics of a bear market?